Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial | MicrobiomeTrials← Back to trialsNCT07167329
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-01-01Est. Completion: 2026-02-01
Enrollment target: 100 participants Locations- AC Camargo Cancer Center, São Paulo, São Paulo, Brazil
Other microbiome trials you might be interested in
Retinal HemangioblastomaVon Hippel-Lindau Disease
Background:
Retinal hemangioblastoma (RH) is a tumor. It grows from the retina in the eye. It can threaten a person s v…
Bethesda, United StatesCompleted Jun 2, 2026
Von Hippel-Lindau DiseaseCarcinoma, Renal Cell
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advan…
Boston, United StatesEst. completion Jan 14, 2034
Phase 2
Recruiting
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorHIF-2α Mutated Cancers
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocy…
Los Angeles, United StatesEst. completion Dec 27, 2029